Decoding the DNA of weight loss drugs (GLP-1s)
The end of impulse? How appetite drugs are redefining consumer choice
GLP-1s are already having a profound impact on consumer behaviours, and it is a question of how – not if – they will continue to shape the market.
By 2030 it is estimated that GLP-1 with have between 30-70 million global users, and 9% of the US population, who are consuming 15-40% fewer calories a day.
This disrupts not only what people eat, but why and how.
Good headway has been made for brands trying to navigate this evolving scenario from the quant perspective. However, at Brand Genetics we believed there was a real need for qualitative depth to ensure the human side of the story wasn’t being forgotten.
The result?
6 months of hard work has given us the deepest, richest and most human-centric lens of how the rise of GLP-1 is impacting the way people think about their relationship with consumption.
Harnessing our proprietary DNA framework shone a light on the creation of a consumer mindset where self-control is the default and traditional cues for indulgence are failing.
To learn more, download our snack-sized report!
